Pharming Group N.V. (PHAR) Revenue & EPS Growth Rates 2026 | EvidInvest

Growth Analysis - PHAR

Financial Metrics

Revenue Trends

Period:

CAGR Performance

Revenue

1Y Growth26.56%

5Y CAGR12.13%

10Y CAGRN/A

Net Income

1Y GrowthN/A

5Y CAGR-40.35%

10Y CAGRN/A

EPS

1Y GrowthN/A

5Y CAGR-41.42%

10Y CAGRN/A

EBIT

1Y GrowthN/A

5Y CAGR-19.46%

10Y CAGRN/A

EBITDA

1Y GrowthN/A

5Y CAGR-21.72%

10Y CAGRN/A

Capex

1Y Growth-5.19%

5Y CAGR-30.61%

10Y CAGRN/A

Equity

1Y Growth25.35%

5Y CAGR8.60%

10Y CAGRN/A

Cash Flow

1Y GrowthN/A

5Y CAGR-8.14%

10Y CAGRN/A

Historical CAGR

Year	1Y CAGR	2Y CAGR	3Y CAGR	5Y CAGR	10Y CAGR	15Y CAGR	20Y CAGR	30Y CAGR
FY 2025 Dec 31, 2025	26.6%	23.8%	22.3%	12.1%	N/A	N/A	N/A	N/A
FY 2024 Dec 31, 2024	21.1%	20.2%	14.3%	9.4%	N/A	N/A	N/A	N/A
FY 2023 Dec 31, 2023	19.3%	11.1%	5.0%	N/A	N/A	N/A	N/A	N/A
FY 2022 Dec 31, 2022	3.4%	-1.6%	2.8%	N/A	N/A	N/A	N/A	N/A
FY 2021 Dec 31, 2021	-6.3%	2.5%	N/A	N/A	N/A	N/A	N/A	N/A
FY 2020 Dec 31, 2020	12.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2019 Dec 31, 2019	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2018 Dec 31, 2018	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Growth Analysis - PHAR

Financial Metrics

Revenue Trends

CAGR Performance

Revenue

Net Income

EPS

EBIT

EBITDA

Capex

Equity

Cash Flow

Historical CAGR

More on Pharming Group N.V.

Compare with peers

Explore

Growth Analysis - PHAR

Financial Metrics

Revenue Trends

CAGR Performance

Revenue

Net Income

EPS

EBIT

EBITDA

Capex

Equity

Cash Flow

Historical CAGR

More on Pharming Group N.V.

Compare with peers

Explore